Haobin Chen, M.D., Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10-CRC, Room 3-5888
- Bethesda, MD 20892
Dr. Chen's research focuses on developing novel epigenetic therapies for the treatment of small cell lung cancer. He is board-certified in internal medicine and medical oncology.
Areas of Expertise
1) small cell lung cancer 2) epigenetics 3) molecular biology
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Small cell lung cancer (SCLC) is a deadly disease and represents 12-15% of all lung cancers. Little progress has been made in its treatment over the past 30 years. Some obstacles against progress are limited systemic treatment options and rapid development of drug resistance. There is an unmet need to understand resistance mechanisms and to develop novel therapies for SCLC.
Gene expression is controlled by epigenetic machinery in cells. Epigenetic therapy targets critical epigenetic machinery in cancer cells to restore normal gene expression and to stop cancer growth. BET bromodomain proteins are emerging epigenetic targets. The use of small molecule inhibitors to target this family of proteins has generated many promising results in liquid tumors, but this approach has not been tested in solid tumors. One of the focuses of my research is to identify which group of SCLC patients would benefit from this novel epigenetic therapy. The other focus of my research is to uncover drug resistance mechanism in SCLC by using a high-throughput screening approach.
Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
Nickel ions inhibit histone demethylase JMJD1A and DNA repair enzyme ABH2 by replacing the ferrous iron in the catalytic centers
Haobin Chen, M.D., Ph.D.
Dr. Chen received his M.D./M.S. degree from Shanghai Medical University (Now Shanghai Medical College Fudan University) in China and his Ph.D. degree from New York University (NYU). He was a research assistant professor at NYU for 4 years, and then completed an internal medicine residency at the Kingsbrook Jewish Medical Center in Brooklyn, NY. He joined the NCI Medical Oncology Branch as a clinical fellow in 2013. He has been a Physician-Scientist Early Investigator in the Thoracic Surgery Branch since 2016.
There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.
Learn more about CCR research advances, new discoveries and more on our news section.